NCT04981665 2022-01-05A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative ResectionZhejiang UniversityPhase 2 Unknown50 enrolled